TVR (Telavic; Mitsubishi Tanabe Pharma, Osaka, Japan) was administrated at a dose of 750 mg every 8 h (2250 mg/day) after food. However, AZD2281 in vitro as phase III trials in Japan are restricted to patients of 65 years of age or less, having normal renal function, TVR was given at a dose of 500 mg every 8 h (1500 mg/day) to patients aged 66 years or older or those having low renal function. Creatinine and estimated glomerular filtration rate (eGFR) were monitored for all patients at day 4 of treatment. As we have reported previously, rapid deterioration of renal function is often observed

after introduction of triple therapy.[12] Therefore, for the patients who started TVR administration at a dose of 2250 mg, if eGFR at day 4 decreased

by more than 20% or more than 20 mL/min per 1.73 m2 compared with that before treatment, the daily TVR dose was reduced from 2250 mg to 1500 mg. The patients were treated with TVR, PEG IFN and RBV for 12 weeks, followed by PEG IFN and RBV for 12 weeks. All patients had a 24-week follow-up period after the last treatment to assess SVR. All patients visited the hospital and had A-769662 solubility dmso a blood test every week. If the Hb concentration had decreased to 2 g/dL or more from the baseline Hb level, 12 000 IU of human recombinant epoetin-α (ESPO; Kyowa Hakko Kirin, Tokyo, Japan) was administrated s.c. If further Hb reduction (≥3 g/dL) GNE-0877 was observed, 24 000 IU of EPO was used. Inosine triphosphatase single nucleotide polymorphism (SNP) (rs1127354) and interleukin-28B SNP (rs8099917) were genotyped by the invader assay for all patients, who gave their informed consent. Serum HCV RNA levels were measured using the COBAS TaqMan HCV test (Roche Diagnostics, Tokyo, Japan). The linear dynamic range was 1.2–7.8 log10 IU/mL. The lower limit of detection was reported as 1.2 log10 IU/mL. Measurements were performed before treatment, at day 4, weeks 1, 2, 3 and 4, and every 2 weeks thereafter during the treatment period,

and weeks 4, 8, 12, 16, 20 and 24 of the follow-up period. SVR was defined as an undetectable HCV RNA level 24 weeks after the end of treatment. FROM FEBRUARY 2012 to June 2012, 22 patients were enrolled in this study (Table 1). They all were infected with HCV-1. There were 14 patients of ITPA genotype CC and 8 patients of non-CC (all of them were of the CA genotype). There were no significant differences between the two groups in baseline characteristics including Hb, renal function and HCV RNA. The clinical features of all patients are shown in Table 2. In three patients, the initial TVR dose was set at 1500 mg/day due to old age (two men) or low eGFR at baseline (one woman). Among the remaining 19 patients, 10 who showed deterioration of renal function at day 4 were given reduced TVR (reduced from 2250 mg to 1500 mg) thereafter. Despite the dose reduction, for one patient (no.